Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes

[1]  C. Croce,et al.  Clinical Applications for microRNAs in Cancer , 2013, Clinical pharmacology and therapeutics.

[2]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[3]  R. Dahiya,et al.  Oncogenic miRNA-182-5p Targets Smad4 and RECK in Human Bladder Cancer , 2012, PloS one.

[4]  Hui Zhang,et al.  miR-96 regulates FOXO1-mediated cell apoptosis in bladder cancer. , 2012, Oncology letters.

[5]  Benjamin R. Lee,et al.  Novel agents and approaches for advanced renal cell carcinoma. , 2012, The Journal of urology.

[6]  A. Scorilas,et al.  Molecular cloning of novel alternatively spliced variants of BCL2L12, a new member of the BCL2 gene family, and their expression analysis in cancer cells. , 2012, Gene.

[7]  A. Scorilas,et al.  Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol , 2012, Tumor Biology.

[8]  Guojun Li,et al.  Lymphangiogenesis and biological behavior in pancreatic carcinoma and other pancreatic tumors , 2012, Molecular medicine reports.

[9]  Hongmei Luo,et al.  hsa-miR-96 up-regulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomas. , 2011, Molecular medicine reports.

[10]  Han Yong Choi,et al.  The epidemiology of renal cell carcinoma. , 2011, European urology.

[11]  A. Fléchon,et al.  Chemotherapy in advanced bladder cancer: current status and future , 2011, Journal of hematology & oncology.

[12]  R A Knight,et al.  Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012 , 2011, Cell Death and Differentiation.

[13]  Ana Kozomara,et al.  miRBase: integrating microRNA annotation and deep-sequencing data , 2010, Nucleic Acids Res..

[14]  E. Sakamoto-Hojo,et al.  Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine , 2010, Experimental biology and medicine.

[15]  Zhiwei Wang,et al.  Implication of microRNAs in drug resistance for designing novel cancer therapy. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[16]  Subbaya Subramanian,et al.  MicroRNAs as gatekeepers of apoptosis , 2010, Journal of cellular physiology.

[17]  Y. Mo,et al.  miR-145-mediated suppression of cell growth, invasion and metastasis. , 2010, American journal of translational research.

[18]  K. D. Sørensen,et al.  miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors , 2010, Oncogene.

[19]  Y Dai,et al.  Microarray analysis of microRNA expression in renal clear cell carcinoma. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[20]  Hailong Wu,et al.  p53 represses c-Myc through induction of the tumor suppressor miR-145 , 2009, Proceedings of the National Academy of Sciences.

[21]  S. Fulda.  Tumor resistance to apoptosis , 2009, International journal of cancer.

[22]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[23]  Liu Hong,et al.  miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells , 2008, International journal of cancer.

[24]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[25]  David S Ziegler,et al.  Therapeutic targeting of apoptosis pathways in cancer , 2008, Current opinion in oncology.

[26]  S. Elmore.  Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.

[27]  A. Scorilas,et al.  Breast Cancer Cells Response to the Antineoplastic Agents Cisplatin, Carboplatin, and Doxorubicin at the mRNA Expression Levels of Distinct Apoptosis‐Related Genes, Including the New Member, BCL2L12 , 2007, Annals of the New York Academy of Sciences.

[28]  Kwang Dong Kim,et al.  Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. , 2006, Cancer letters.

[29]  E. Mini,et al.  Cellular pharmacology of gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Andreas Scorilas,et al.  BCL2 Family of Apoptosis-Related Genes: Functions and Clinical Implications in Cancer , 2006, Critical reviews in clinical laboratory sciences.

[31]  Rui Shi,et al.  Facile means for quantifying microRNA expression by real-time PCR. , 2005, BioTechniques.

[32]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  N. Chandler,et al.  Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine , 2003, Journal of Gastrointestinal Surgery.

[34]  Dah-Shyong Yu,et al.  The Expression of Oncoproteins in Transitional Cell Carcinoma: Its Correlation with Pathological Behavior, Cell Cycle and Drug Resistance , 2002, Urologia Internationalis.

[35]  V. Dixit,et al.  Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis. , 2001, Journal of cell science.

[36]  A. Scovassi,et al.  Poly(ADP-ribose) polymerase cleavage during apoptosis: when and where? , 2001, Experimental cell research.

[37]  G. J. van Steenbrugge,et al.  Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells. , 2001, Anticancer research.

[38]  G. Poirier,et al.  Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases , 2001, Cell Death and Differentiation.

[39]  L. Ashworth,et al.  Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. , 2001, Genomics.

[40]  I. Tannock,et al.  Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs , 2001, British Journal of Cancer.

[41]  G. Peters,et al.  Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. , 2000, Cancer research.

[42]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[43]  W. Plunkett,et al.  Induction of apoptosis by gemcitabine. , 1995, Seminars in oncology.

[44]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[45]  E. Eisenhauer,et al.  Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  P. Nowell,et al.  A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[47]  W. Newhall,et al.  The use of Tween 20 as a blocking agent in the immunological detection of proteins transferred to nitrocellulose membranes. , 1982, Journal of immunological methods.

[48]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[49]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[50]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[51]  Hong-zhao Li,et al.  Differential miRNA expression profiles in bladder urothelial carcinomas. , 2010, Asian Pacific journal of cancer prevention : APJCP.

[52]  L. Weissbach,et al.  Gemcitabine: A phase II study in patients with advanced renal cancer , 2009, Cancer Chemotherapy and Pharmacology.

[53]  W. Schulz,et al.  Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines , 2004, Urological Research.

[54]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.